Community Nursing Yukon Immunization Program Section 8 Biological Products 2011 March SECTION 8 BIOLOGICAL PRODUCTS TABEL OF CONTENTS DIPHTHERIA - TETANUS- ACELLULAR PERTUSSIS - HEPATITIS B- POLIO- HAEMOPHILUS INFLUENZAE TYPE B ADSORBED (DTAP- HB- IPV- HIB) (INFANRIX HEXA )3 DIPHTHERIA -TETANUS - ACELLULAR PERTUSSIS-POLIO-HAEMOPHILUS INFLUENZAE TYPE B ADSORBED (DTAP-IPV-HIB) (PEDIACEL ).4 DIPHTHERIA-TETANUS- ACELLULAR PERTUSSIS - POLIO ADSORBED (DTAP-IPV) (QUADRACEL ).5 HAEMOPHILUS B CONJUGATE VACCINE (ACT-HIB ).6 HEPATITIS A VACCINE: INDICATIONS.7 HEPATITIS A VACCINE (INACTIVATED VIRAL) (HAVRIX ) 8 HEPATITIS A VACCINE (INACTIVATED VIRAL) (VAQTA )10 HEPATITIS B VACCINE PRE-EXPOSURE INDICATIONS 11 HEPATITIS B VACCINE (ENGERIX -B).12 HEPATITIS B VACCINE PRE-EXPOSURE (RECOMBIVAXHB ) (10 MCG/1.0 ML)13 HEPATITIS B VACCINE POST-EXPOSURE INDICATIONS15 HEPATITIS B IMMUNE GLOBULIN (HBIG) (BAYHEP B ) 17 HEPATITIS B VACCINE POST EXPOSURE (RECOMBIVAXHB ) (10 MCG/1.0 ML)19 HEPATITIS B VACCINE PROGRAM FOR CHRONIC KIDNEY DISEASE CLIENTS.20 HUMAN PAPILLOMAVIRUS VACCINE (GARDASIL ).21 SEASONAL TRIVALENT INFLUENZA VACCINE (INACTIVATED SPLIT VIRION OR SUBUNIT).23 INFLUENZA VACCINE (INACTIVATED SPLIT VIRION) (FLUVIRAL )24 JAPANESE ENCEPHALITIS VACCINE (IXIARO ) 25 MEASLES/MUMPS/RUBELLA VACCINE (LIVE ATTENUATED VIRAL) MMRII sickle cell disease; immunosuppression related to disease (e.g., congenital immunodeficiency states such as complement, properdin or factor D deficiency; malignant neoplasm including leukemia and lymphoma; HIV infection) or therapy (e.g., high dose, systemic steroids; or severe rheumatoid arthritis requiring immunosuppressive therapy); candidates or recipients of solid organ or islet cell transplants, or cochlear implants: 0.5 ml IM (1 dose) No reinforcement required (3)Re-immunization following receipt of a hematopoietic stem cell transplant (HSCT) 0.5 ml IM (3 doses) CONTRAINDICATIONS History of anaphylactic reaction to a previous dose of a Hib- containing vaccine or to any component of Act-HIB . VACCINE COMPONENTSTetanus protein and Trometamol. ADVERSE EVENTSMinor Local: redness, tenderness, swelling, pain. Minor Systemic: fever 38.3 C, fussiness, irritability, lethargy, loss of appetite. It is preferable to use the same Hib product for all doses of the primary series. Using different Hib products during the primary series is acceptable if it is not possible to continue with the initial product. Children who had Hib disease prior to 24 months of age may not have mounted an adequate immune response for protection against Hib disease and should receive vaccine according to the schedule consistent with their age. If series is interrupted, complete series according to age at which child re-presents. The booster recommended at 18 months may be given as early as 15 months provided there is a 2 month interval following the previous dose. At 15 months of age and older, a single dose of any Hib product is all that is required for protective antibody levels. Give vaccine at least 14 days prior to elective splenectomy, or if not possible, 14 or more days post-splenectomy. If there is concern that the patient may not present later for immunization, give vaccine before discharge. One Hib dose is recommended for children and adult asplenics 5 years of age, regardless of previous Hib immunization. Contact the Vaccine Program Manager prior to immunization for this indication. Community Nursing Yukon Immunization Program Biological Products March 2011 Page 7 Hepatitis A Vaccine: Indications Recommended and provided free to: Individuals with haemophilia A or B receiving plasma-derived replacement clotting factors and testing negative for anti-HAV IgG/HAV total (combined IgM persons sharing illicit drug snorting, smoking or injecting equipment. Men who have sex with men. Individuals with sexual life-style risks of infection where there is a likelihood of oral-anal contact. Individuals who are HIV positive. Inmates of correctional facilities in which there is epidemiological evidence of sustained Hepatitis A infection (on order of Medical Officer of Health only). Haematopoietic stem cell transplant (HSCT) recipients. Individuals receiving chronic blood transfusions. Contacts of a confirmed case of hepatitis A: Household, Close non-household, Daycare, Drug-sharing, Sexual contacts, Other food handlers at the same establishment if the case is a food handler, Patrons of involved food-handling establishment at risk of hep A as assessed by Public Health staff. Recommended but not provided free to: Travelers, military personnel, and others who will work or live in countries with intermediate or high endemic rates of HAV infection, especially when travel or work will involve rural or primitive conditions. Persons with multiple sex partners. Food handlers. Employees who have been directed to receive this immunization, as per employer dire